hospitalized in an acute state of the depressive phase, and they did not receive therapy for more than 6 months. Blood was collected before the start of therapy. Serum was purified from major proteins by affinity chromatographyandseparatedby1D-electrophoresis. After trypsinolysis, the proteins were identified by HPLC/mass spectrometry. The ELISA kit was used to determine the amount of zNMDAR1.

**Results:** We identified a protein that does not occur in healthy people: a subunit of the glutamate NMDA receptor zeta-1 (zNMDAR1). As a result, we found a statistically significant (p = 0.037) almost fivefold increase in the concentration of this protein in the serum of patients with bipolar disorder (0.64 [0.18; 0.78] ng/ml) compared with healthy individuals.

**Conclusions:** Thus, in bipolar disorder NMDAR is damaged, which can lead appearance of their subunits in the serum, and which indicated a violation of glutamatergic neurotransmission. Then this protein claims the role of markers of bipolar disorder. *Mass spectrometric analysis was carried out of the "Human Proteome" Core Facility of the Institute of Biomedical Chemistry Moscow. RSW project, state registration number AAAA-A19-119020690013-2.* 

**Disclosure:** No significant relationships. **Keywords:** bipolar disorder; proteomics; biomarker

## **EPP0090**

## The Relationships Between Strategies Of Stress Coping And Temperament-Character Traits In Subjects With Bipolar Disorder

I. Gundogmus<sup>1</sup>, S. Tekin<sup>2\*</sup>, A.B. Yasar<sup>3</sup> and Ö. Uzun<sup>2</sup>

<sup>1</sup>Kırıkkale Yüksek İhtisas Hospital, Psychiatry, Ankara, Turkey;
<sup>2</sup>Gulhane Research and Training Hospital, Psychiatry, Ankara, Turkey and <sup>3</sup>Istanbul Gelisim University, Psychiatry, Istanbul, Turkey
\*Corresponding author.
doi: 10.1192/j.eurpsy.2022.418

**Introduction:** Bipolar disorder (BD) is a severe mood disorder, which is characterized by a cycling between the mania and major depression. The relationship between coping strategies and temperament-character traits in BD is unclear at this time.

**Objectives:** The aim of our study was to assess the relationship between strategies of coping stress and temperament-character traits in individuals with BD.

**Methods:** 168 patients diagnosed with BD in full remission were included. All participants were diagnosed by an experienced consultant psychiatrist based on DSM-5 and were assessed with Young Mania Rating Scale (YMRS) for confirmation to remission. Sociodemographic datas of all participants was obtained and Temperament Evaluation of Memphis, Pisa, Paris and San Diego-Autoquestionnaire (TEMPS-A) and Coping with Stress Scale (CSS) were applied.

**Results:** 75 patients (44.6%) were female and the mean age of the sample was  $32.64\pm10.74$  years, the mean duration of illness was  $8.23\pm5.52$  years and was found that the mean score of YMRS  $5.35\pm4.19$ . It was presented Table 1 whether there was a statistically significant correlation between TEMPS-A and CSS subscales.

**Conclusions:** As coping strategies may be related to temperamentcharacter traits and that could be important for psychological interventions in patients with BD.

	Depressive	Hypertimic	Cyclothymic	Irritable	Anxious
Avoidance	-,067	-,159	,098	-,150	-,083
	,485	,095	,305	,115	,387
Problem-focused coping strategies	-,268	-,153	,366	-,246	-,134
	,004	,109	,000	-,009	,161
Social support	-,191	-,495	-,060	-,646	-,416
	,044	,000	,535	,000	,000
Total	-,256	-,399	,149	-,370	-,324
	,007	,000	,118	,000	,001

Disclosure: No significant relationships.

**Keywords:** bipolar disorders; strategies of stress coping; temperament-character traits

## **EPP0091**

## Cariprazine's efficacy in treating affective symptoms – pooled data from schizophrenia and bipolar depression trials

R. Mcintyre<sup>1</sup>, Z. Dombi<sup>2\*</sup>, Á. Barabássy<sup>2</sup> and G. Németh<sup>2</sup>

<sup>1</sup>University of Toronto, Department Of Psychiatry And Pharmacotherapy, Toronto, Canada and <sup>2</sup>Gedeon Richter Plc, Medical Division, Budapest, Hungary \*Corresponding author. doi: 10.1192/j.eurpsy.2022.419

**Introduction:** Affective symptoms are a common feature of schizophrenia and define bipolar disorder. Alterations in dopamine neurotransmission and activity at  $D_3$ - $D_2$  receptors is associated with depressive symptoms providing the rationale for targeting  $D_3$ - $D_2$  receptors with partial agonists.

**Objectives:** The aim of the analysis herein is to examine and compare the efficacy of cariprazine in treating affective symptoms in both schizophrenia and bipolar depression.

Methods: Data from 3 schizophrenia [NCT00694707, NCT01104766, NCT01104779] and 3 bipolar I depression studies [NCT013896447, NCT02670538, NCT0267055] were pooled for the analyses. To investigate efficacy across individual affective symptoms, the Marder anxiety/depression and negative symptom items of the Positive and Negative Syndrome Scale (PANSS) and single items of the Montgomery-Asberg Depression Rating Scale (MADRS) were analysed. Improvement across affective symptoms was examined primarily evaluating least square mean differences (LSMDs) in comparison to placebo in mean change from baseline. Results: The pooled ITT population was comprised of persons with schizophrenia (placebo=442, cariprazine=1024) and bipolar disorder (placebo=460, cariprazine=923). Cariprazine resulted in a significantly greater reduction when compared to placebo in three out of the four Marder anxiety/depression items; anxiety (p<0.01), tension (p<0.001) and depression (p<0.05). Similarly, cariprazine was significantly better than placebo in 9 out of the 10 MADRS individual items; apparent sadness (p<0.001), reported sadness (p<0.001), reduced sleep (p<0.05), reduced appetite (p<0.001), concentration difficulties